This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified member
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
English to Spanish: Sample Translation: Medicine - Medicina
Source text - English To prepare the vaccine, melanoma cells are irradiated and transduced with rAAV vectors as vehicle for the therapeutic genes B7.2 and GM-CSF. After further cell cultivation, the cells are trypsinized, washed, frozen, thawed, and finally injected into a patient.
Given a patient dose of 107 vaccine cells, at maximum 106 transducing rAAV particles and 103 rcAAV particles are injected into a patient. Replication and biodistribution of rAAV is only possible if the same cell is coinfected with at least one rAAV, one rcAAV and one helper virus particle. Given the number of particles above, the chance for such an event is very unlikely. Nevertheless, if a cell was infected by all 3 types of viruses, a preferential replication of rcAAV would occur, because rcAAV as close-to wild type variant has a clear selection advantage over rAAV. Finally, recombination between rcAAV and rAAV, leading to a replication-competent recombinant virus harboring the foreign (therapeutic) genes can never occur, because the genome of such a fictitious particle would be much larger than the well defined packaging capacity of AAV particles (approx. 5 kb at maximum).
Beside the fact that AAV can only replicate in the presence of helper viruses, it is important to mention that AAV is a non-pathogenic virus and, therefore, a very safe vector system. Furthermore, around 70-80 % of the human population is seropositive for AAV-2, the serotype used for generation of our recombinant vectors. Because AAV-2 persists in a latent state via specific integration into human chromosome 19, it is very likely that most humans are carrier for AAV genomes. However until now, there is no systematic investigation with regard to the natural biodistribution of AAV in man. Furthermore, patients with acute infections of HSV or Ad will be excluded from the study to minimize the risk of rAAV replications in vivo.
Translation - Spanish Para preparar la vacuna, se irradian células de melanoma y se transducen con vectores rAAV como vehículo para los genes terapéuticos B7.2 y GM-CSF Después de cultivo celular adicional, las células son tripsinizadas, lavadas, congeladas, descongeladas y finalmente se inyectan a un paciente.
Una dosis de paciente dada de 107 células vacuna, al máximo 106 partículas transductoras rAAV y 103 partículas rcAAV inyectada a un paciente. La Replicación y bio-distribución de rAAV es posible solo si la misma célula está co-infectada con por lo menos una rAAV, una rcAAV y una partícula auxiliar o helper. Dado el número de partículas mencionado arriba, las probabilidades para que esto suceda son muy pocas. Sin embargo. Si una célula fue infectada por los tres tipos de virus, ocurriría una replicación preferencial de rcAAV ya que el rcAAV, tan cercano a una variante salvaje tiene una ventaja clara de selección sobre rAAV. Finalmente, la recombinación entre rcAAV y rAAV, que conducen a un virus recombinante con capacidad de replicación y que contenga los genes ajenos (terapéuticos) nunca ocurrirá, ya que el genoma de esta partícula tan ficticia sería mucho mas grande que la bien definida capacidad de empaque de partículas AAV (aprox., 5 kb al máximo).
Además del hecho de que AAV solo puede replicarse en presencia de virus auxiliares, es importante mencionar que AAV es un virus no patógeno y por lo tanto muy seguro como sistema vector. Adicionalmente, aproximadamente el 70-80% de la población humana es sero-positiva para AAV-2, el serotipo utilizado para la generación de nuestros vectores recombinantes. Dado que AAV-2 persiste en estado latente a través de integración especifica al cromosoma 19 humano, es muy probable que la mayoría de los humanos sean portadores de genomas AAV. Sin embargo, hasta ahora, no existe una investigación sistemática con respecto a la bio-distribución natural de AAV en el hombre. Adicionalmente, los pacientes con infecciones agudas de HSV o Ad serán excluidos del estudio para minimizar el riesgo de replicaciones en vivo de rAAV.
More
Less
Experience
Years of experience: 43. Registered at ProZ.com: Oct 2000. Became a member: Sep 2008.
I am a medical doctor educated in Mexico where my Spanish has never been contaminated; I have 100% understanding of English and work very fast
I have completed technical manuals for API an air pollution device manufacturer for approximately 5 cents per word. Conference translation of pediatrics convention. Ongoing safety training materials for the steel industry. Health handouts for patients for a major medical organization.
Recently doing online surveys for pharmaceutical industry applied to doctors.
Resume available upon request.
Traducción de todo tipo de documentos especialmente volúmenes grandes.
Manuales, instructivos, contratos.
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
Member since Sep '08
Expertise 